Combining Omalizumab with Another Biotherapy.

The article presents a study of 6 women and 4 men, with a mean age of 37.6 years to investigate the safety and efficacy of combined biotherapy comprising of omalizumab. It mentions that patients with chronic spontaneous urticaria (CSU) are at risk of autoimmune diseases such as Hashimoto's thyroiditis, and pernicious anemia; and also mentions combining omalizumab with biologic drugs of different mechanism of action, should not be associated with beneficial or detrimental interactions.